Hospira Inc., which operates as part of Pfizer, recently issued a voluntary recall for its Sodium Bicarbonate Injection, USP because of a particulate that has been found in a single-dose glass flip-top vial.

A team of researchers at the Mayo Clinic in Jacksonville, Florida, has discovered a new disease mechanism in the C9orf72 gene, which is the most common genetic type of ALS.

The U.S. Food and Drug Administration (FDA) recently released a proposal that would ban the majority of the powdered gloves that are used in the medical industry within the U.S.

A team of scientists has received funding from the National Institutes of Health (NIH) to find the molecule that is responsible for sperm activation, which could help the researchers create infertility treatments and male contraceptives.

AAFP President Wanda Filer recently joined a panel discussion about the growth of antibiotic resistance and how it will change treatments for patients in the future.

GSK scientists recently released the results from their study for a pediatric long acting beta2-agonist (LABA) safety trial, which compared Advair Diskus to FP monotherapy treatments for children between the ages of four and 11 years old.

An estimated 24 million people in the U.S. live with autoimmune diseases, and as this number rises, so does the demand for more related research and solutions.

March 2016 set the latest record for matching medical students and graduates with family medicine, selecting 3,105 graduating medical students who wanted to be in family medicine with the National Resident Matching Program.

GlaxoSmithKline (GSK) and Miltenyi Biotec have partnered to unite the cell and gene therapy-based treatments from GSK, with the cell processing and related cell therapy technologies from Miltenyi Biotec.

The Lupus Foundation of America recently created the Collective Data Analysis Initiative (LFA CDAI) to improve clinical trials for lupus, in an effort to speed the development of new lupus therapies.

Merck KGaA, Darmstadt, Germany, a top technology and science company, recently announced that it has launched its worldwide phase-three clinical study of MSB11022, which is a proposed biosimilar containing adalimumab, to determine whether it is helpful in treating inflammatory diseases like chronic plaque psoriasis.

A team of researchers from Brown University recently conducted a study to clarify the discrepancies of countless fundamental studies about the biology of aging, using a model of C. elegans worms as they age.

VBI Vaccines Inc. recently released new data that shows positive results from its glioblastoma multiforme cancer immunotherapy program.

Amgen recently announced that it has submitted a supplemental Biologics License Application (sBLA) for the company’s Blincyto drug to the U.S. Food and Drug Administration (FDA).

The ALS Association recently invested approximately $2.5 million in the Translational Research Advancing Therapy for ALS (TREAT ALS) Drug Development Contract grant program, designed to develop new ALS treatments.

Dan Durham, executive vice president of Health Policy at Biotechnology Innovation Organization (BIO), recently made a statement about the White House decision to advance the Precision Medicine Initiative.

The U.S. Food and Drug Administration (FDA) recently stated that there is now a total of $2 million in research grants available to finance natural history studies of rare diseases.

AstraZeneca and MedImmune, the worldwide biologics research and development branch, recently released the top-line results from their tremelimumab monotherapy trial involving mesothelioma.

The FDA recently approved Afinitor, a new drug from Novartis that is designed to treat progressive, nonfunctional gastrointestinal as well as lung neuroendocrine tumors.

The American Academy of Family Physicians (AAFP) recently published a paper calling for the incorporation of preconception care into patient visits. Preconception care first become popular during the 1980s.